Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death

Circulation Journal

Volumn 71, Issue 11, 2007, Pages 1815-1820

  Ikegami, Ei ^a   Fukazawa, Ryuji ^a,b   Kanbe, Masaru ^a   Watanabe, Miki ^a   Abe, Masanori ^a   Watanabe, Makoto ^a   Kamisago, Mitsuhiro ^a   Hajikano, Miharu ^a   Katsube, Yasuhiro ^a   Ogawa, Shunichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

Author keywords

Apoptosis; Cardiomyopathy; Edaravone; Necrosis; Redox cycling

Indexed keywords

ANTHRACYCLINE; CASPASE 3; DAUNORUBICIN; DOXORUBICIN; LACTATE DEHYDROGENASE; MANGANESE SUPEROXIDE DISMUTASE; NORPHENAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CELL CULTURE; CELL DEATH; CELL STRAIN K 562; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA HISTONE INTERACTION; DRUG EFFECT; ELECTROCARDIOGRAM; ENZYME ACTIVITY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; IN VIVO STUDY; NONHUMAN; RAT;

ANIMALS; ANTHRACYCLINES; ANTIPYRINE; APOPTOSIS; CASPASE 3; CELL SURVIVAL; CELLS, CULTURED; DAUNORUBICIN; FREE RADICAL SCAVENGERS; L-LACTATE DEHYDROGENASE; MYOCYTES, CARDIAC; NECROSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 36949015405     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1815     Document Type: Article

References (32)

1. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
2. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985; 55: 2761-2765.
3. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, et al. Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981; 94: 430-435.
4. Fukazawa R, Ogawa S, Hirayama T. Early detection of anthracycline cardiotoxicity in children with acute leukemia using exercise-based echocardiography and Doppler echocardiography. Jpn Circ J 1994;58:625-634.
5. Uchikoba Y, Hino Y, Katsube Y, Ohkubo T, Kuramochi Y, Fukumi D, et al. Evaluation of acute and chronic anthracycline cardiotoxicity in children with acute leukemia bv signal averaged electrocardiogram. Sinzou 2000; 32(Suppl 1): 29-33.
6. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II: Formation of superoxide anion, hydrogen peroxide. and hydroxyl radical. J Biol Chem 1986; 261: 3068-3074.
7. Doroshow JH, Locker GY, Myers CL. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin invest 1980; 65: 128-135.
8. The Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCl-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15: 222-229.
9. Abe S, Kirima K, Tsuchiya K, Okamoto M, Hasegawa T, Houchi H. et al. The reaction rate of edaravone (3-metliyl-1-plienyl-2-pyrazolin-5-one (MCI-186)) with hydroxyl radical. Chem Pharm Bull (Tokyo) 2004; 52: 186-191.
10. Springhurn JP, Ellingsen O, Berger HJ, Kelly RA, Smith TW. Transcriptional regulation in cardiac muscle: Coordinate expression of Id with a neonatal phenotype during development and following a hypertrophic stimulus in adult rat ventricular myocytes in vitro. J Biol Chem 1992; 267: 14360-14365.
11. Holdenrieder S, Stieber P, Bodenmuller H, Fertig G, Furst H. Schindler N, et al. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001; 39: 596-605.
12. Chao W, Shen Y, Li L. Rosenzweig A. Importance of FADD signaling in serum deprivation- and hypoxia-induced cardiomyocyte apoptosis. J Biol Chem 2002; 277: 31639-31645.
13. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002; 106: 1403-1409.
14. Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N. Neuroprotective effects of edaravone: A novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006; 12: 9-20.
15. Yagi H, Horinaka S, Matsuoka H. Edaravone prevented deteriorated cardiac function after myocardial ischemia-reperfusion via inhibiting lipid peroxidation in rat. J Cardiovasc Pharmacol 2005; 46: 46-51.
16. Fsujita K, Shimomura H, Kaikita K, Kawano H, Hokamaki J, Nagayoshi Y, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J 2006; 70: 832-837.
17. Xi H, Akishita M, Nagai K, Yu W, Hasegawa H, Eto M, et al. Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. Atherosclerosis 2006; 191: 281-289.
18. Dorr RF. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23(Suppl 8): 23-34.
19. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91: 10-15.
20. Dragojevic-Simic VM, Dobric SL, Bokonjic DR, Vucinic ZM, Sinovec SM, Jacevic VM, et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 2004; 15: 169-178.
21. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcystcinc. Semin Oncol 1983; 10(Suppl 1): 53-55.
22. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. Protective effects of Carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999; 65: 1265-1274.
23. Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198): and other chelating agents with the Fe(III) and Cu (II) complexes of adriamycin. Agents Actions 1989; 26: 378-385.
24. Herman EH, Ferrans VJ, Young RSK, Hamlin RL. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 1988; 48: 6918-6925.
25. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-752.
26. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-127.
27. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15: 1333-1340.
28. Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112-3120.
29. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-153.
30. van Dalen EC, Caron HN. Dickinson HO, Kreiner LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005; 25: CD003917.
31. Schlichter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-2903.
32. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999; 84: 257-265.